Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

The Potential Impact of the New Presidential Administration on the Future of the Inflation Reduction Act and Broader Healthcare Policy

January 20, 2025 |  

Discover the key takeaways from OPEN Health’s latest whitepaper: “The Potential Impact of the New Presidential Administration on the Future of the Inflation Reduction Act and Broader Healthcare Policy.”

IRA whitepaper_OPEN Health

Discover the key takeaways from OPEN Health’s latest whitepaper The Potential Impact of the New Presidential Administration on the Future of the Inflation Reduction Act and Broader Healthcare Policy:

  • Review of President Trump’s healthcare policies during his first term: Attempts to repeal the Affordable Care Act (ACA), drug pricing initiatives, and Medicare and Medicaid policies.
  • A look into the future of the Inflation Reduction Act (IRA) and broader healthcare policy in the US: The potential impact of the incoming administration on the healthcare provisions of the IRA and other statements by President Trump focused on healthcare policy.

Read the full whitepaper to understand how these developments could influence healthcare decision-making and strategy. View the whitepaper here.

Working in partnership with our clients, we embrace our different perspectives and strengths to deliver fresh thinking and solutions that make a difference. Together we can unlock possibilities. For information about OPEN Health’s services and how we could support you, please get in touch. 

This content was provided by OPEN Health

Company Details

OPEN Health

OPEN Health

Email
Website

 Latest Content from  OPEN Health 

OPEN Health’s response to the FDA’s guidance on long term follow up post gene therapy

Written by Gavin Jones, OPEN Health

OPEN Health expands offering with the launch of a new Learning & Development specialist team

Enhanced expertise to deliver impactful internal training programmes for healthcare clients

Spotlight interview: 15 minutes on healthcare communications in gene therapy

Gavin Jones, Director of Rare Disease, OPEN Health takes 15 minutes to answer some key questions on healthcare communications in gene therapy

OPEN Health becomes sponsor of MedComms Networking

New for 2020, OPEN Health is pleased to announce its sponsorship of MedComms Networking

OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications

Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications

Spotlight interview: 15 minutes on digital in medical communications

Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications

Generating data on long-term outcomes with gene and other advanced therapies

Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’.

Are you using Patient-Reported Outcomes (PROs) in your oncology trials? If not, why not?

A recent blog, published by Sarah Tressel Gary and Rinah Yamamoto called “Patient-Reported Outcome Data in Oncology Trials - Part 2: Clinical Benefit and Patient Preference”, has sparked our interest....

Spotlight interview: 15 minutes on insights and market research in pharma

Neil Rees, Head of Research, OPEN Health Patient & Brand Communication takes 15 minutes to answer some key questions on insights and market research in pharma

OPEN Health reflections on the World Orphan Drug Congress in Barcelona

Having just returned from a very busy but hugely enjoyable few days at congress, I wanted to share our views on the event and key themes that our healthcare communications...